 | • レポートコード：MRC23Q37005 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のサイクリン依存性キナーゼ（CDK）阻害剤市場について調査・分析し、世界のサイクリン依存性キナーゼ（CDK）阻害剤市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（経口、静脈注射、その他）、用途別セグメント分析（病院、薬局、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Sanofi、Pfizer Inc.、Eli Lilly and Company、Novartis、Astex Pharmaceuticals、Bristol-Myers Squibb Company、Merck KGaA、AstraZenecaなどが含まれています。 世界のサイクリン依存性キナーゼ（CDK）阻害剤市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、サイクリン依存性キナーゼ（CDK）阻害剤市場規模を推定する際に考慮しました。本レポートは、サイクリン依存性キナーゼ（CDK）阻害剤の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、サイクリン依存性キナーゼ（CDK）阻害剤に関するビジネス上の意思決定に役立てることを目的としています。 ・サイクリン依存性キナーゼ（CDK）阻害剤市場の概要 - 製品の定義 - サイクリン依存性キナーゼ（CDK）阻害剤のタイプ別セグメント - 世界のサイクリン依存性キナーゼ（CDK）阻害剤市場規模：タイプ別分析（経口、静脈注射、その他） - サイクリン依存性キナーゼ（CDK）阻害剤の用途別セグメント - 世界のサイクリン依存性キナーゼ（CDK）阻害剤市場規模：用途別分析（病院、薬局、その他） - 世界のサイクリン依存性キナーゼ（CDK）阻害剤市場規模予測（2018年-2029年） - サイクリン依存性キナーゼ（CDK）阻害剤の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - サイクリン依存性キナーゼ（CDK）阻害剤市場の競争状況およびトレンド ・サイクリン依存性キナーゼ（CDK）阻害剤の地域別市場規模 - 北米のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - アメリカのサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - ヨーロッパのサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - アジア太平洋のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - 中国のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - 日本のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - 韓国のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - インドのサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - オーストラリアのサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - 中南米のサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） - 中東・アフリカのサイクリン依存性キナーゼ（CDK）阻害剤市場規模（2018年-2029年） ・タイプ別セグメント：経口、静脈注射、その他 - 世界のサイクリン依存性キナーゼ（CDK）阻害剤のタイプ別販売量（2018年-2023年） - 世界のサイクリン依存性キナーゼ（CDK）阻害剤のタイプ別売上（2018年-2023年） - 世界のサイクリン依存性キナーゼ（CDK）阻害剤のタイプ別価格 ・用途別セグメント：病院、薬局、その他 - 世界のサイクリン依存性キナーゼ（CDK）阻害剤の用途別販売量（2018年-2023年） - 世界のサイクリン依存性キナーゼ（CDK）阻害剤の用途別売上（2018年-2023年） - 世界のサイクリン依存性キナーゼ（CDK）阻害剤の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Sanofi、Pfizer Inc.、Eli Lilly and Company、Novartis、Astex Pharmaceuticals、Bristol-Myers Squibb Company、Merck KGaA、AstraZeneca ・産業チェーンと販売チャネルの分析 - サイクリン依存性キナーゼ（CDK）阻害剤産業チェーン分析 - サイクリン依存性キナーゼ（CDK）阻害剤の主要原材料 - サイクリン依存性キナーゼ（CDK）阻害剤の販売チャネル - サイクリン依存性キナーゼ（CDK）阻害剤のディストリビューター - サイクリン依存性キナーゼ（CDK）阻害剤の主要顧客 ・サイクリン依存性キナーゼ（CDK）阻害剤市場ダイナミクス - サイクリン依存性キナーゼ（CDK）阻害剤の業界動向 - サイクリン依存性キナーゼ（CDK）阻害剤市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Cyclin-Dependent Kinase (CDK) Inhibitors market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Cyclin-Dependent Kinase (CDK) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cyclin-Dependent Kinase (CDK) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Cyclin-Dependent Kinase (CDK) Inhibitors include Sanofi, Pfizer Inc., Eli Lilly and Company, Novartis, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Merck KGaA and AstraZeneca, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cyclin-Dependent Kinase (CDK) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cyclin-Dependent Kinase (CDK) Inhibitors.
The Cyclin-Dependent Kinase (CDK) Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cyclin-Dependent Kinase (CDK) Inhibitors market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cyclin-Dependent Kinase (CDK) Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Sanofi
Pfizer Inc.
Eli Lilly and Company
Novartis
Astex Pharmaceuticals
Bristol-Myers Squibb Company
Merck KGaA
AstraZeneca
Segment by Type
Oral
Intravenous Injection
Others
Segment by Application
Hospital
Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cyclin-Dependent Kinase (CDK) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cyclin-Dependent Kinase (CDK) Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Cyclin-Dependent Kinase (CDK) Inhibitors Market Overview
1.1 Product Overview and Scope of Cyclin-Dependent Kinase (CDK) Inhibitors
1.2 Cyclin-Dependent Kinase (CDK) Inhibitors Segment by Type
1.2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Value Comparison by Type (2023-2029)
1.2.2 Oral
1.2.3 Intravenous Injection
1.2.4 Others
1.3 Cyclin-Dependent Kinase (CDK) Inhibitors Segment by Application
1.3.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue 2018-2029
1.4.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales 2018-2029
1.4.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Cyclin-Dependent Kinase (CDK) Inhibitors Market Competition by Manufacturers
2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Manufacturers (2018-2023)
2.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Average Price by Manufacturers (2018-2023)
2.4 Global Cyclin-Dependent Kinase (CDK) Inhibitors Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Cyclin-Dependent Kinase (CDK) Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cyclin-Dependent Kinase (CDK) Inhibitors, Product Type & Application
2.7 Cyclin-Dependent Kinase (CDK) Inhibitors Market Competitive Situation and Trends
2.7.1 Cyclin-Dependent Kinase (CDK) Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cyclin-Dependent Kinase (CDK) Inhibitors Players Market Share by Revenue
2.7.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cyclin-Dependent Kinase (CDK) Inhibitors Retrospective Market Scenario by Region
3.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region: 2018-2029
3.2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region: 2018-2023
3.2.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Region: 2024-2029
3.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region: 2018-2029
3.3.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region: 2018-2023
3.3.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Region: 2024-2029
3.4 North America Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.4.1 North America Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.4.3 North America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.5.1 Europe Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.5.3 Europe Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.6.3 Asia Pacific Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.7.3 Latin America Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cyclin-Dependent Kinase (CDK) Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Cyclin-Dependent Kinase (CDK) Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Country (2018-2029)
3.8.3 Middle East and Africa Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Type (2018-2029)
4.1.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Type (2018-2023)
4.1.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Type (2024-2029)
4.1.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Type (2018-2029)
4.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Type (2018-2029)
4.2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Type (2018-2023)
4.2.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Type (2024-2029)
4.2.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Type (2018-2029)
4.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Price by Type (2018-2029)
5 Segment by Application
5.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Application (2018-2029)
5.1.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Application (2018-2023)
5.1.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales by Application (2024-2029)
5.1.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Sales Market Share by Application (2018-2029)
5.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Application (2018-2029)
5.2.1 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Application (2018-2023)
5.2.2 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue by Application (2024-2029)
5.2.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Revenue Market Share by Application (2018-2029)
5.3 Global Cyclin-Dependent Kinase (CDK) Inhibitors Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Sanofi Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Pfizer Inc.
6.2.1 Pfizer Inc. Corporation Information
6.2.2 Pfizer Inc. Description and Business Overview
6.2.3 Pfizer Inc. Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Pfizer Inc. Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.2.5 Pfizer Inc. Recent Developments/Updates
6.3 Eli Lilly and Company
6.3.1 Eli Lilly and Company Corporation Information
6.3.2 Eli Lilly and Company Description and Business Overview
6.3.3 Eli Lilly and Company Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Eli Lilly and Company Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.3.5 Eli Lilly and Company Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Astex Pharmaceuticals
6.5.1 Astex Pharmaceuticals Corporation Information
6.5.2 Astex Pharmaceuticals Description and Business Overview
6.5.3 Astex Pharmaceuticals Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Astex Pharmaceuticals Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.5.5 Astex Pharmaceuticals Recent Developments/Updates
6.6 Bristol-Myers Squibb Company
6.6.1 Bristol-Myers Squibb Company Corporation Information
6.6.2 Bristol-Myers Squibb Company Description and Business Overview
6.6.3 Bristol-Myers Squibb Company Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bristol-Myers Squibb Company Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.6.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.7 Merck KGaA
6.6.1 Merck KGaA Corporation Information
6.6.2 Merck KGaA Description and Business Overview
6.6.3 Merck KGaA Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck KGaA Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.7.5 Merck KGaA Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Corporation Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Cyclin-Dependent Kinase (CDK) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.8.4 AstraZeneca Cyclin-Dependent Kinase (CDK) Inhibitors Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cyclin-Dependent Kinase (CDK) Inhibitors Industry Chain Analysis
7.2 Cyclin-Dependent Kinase (CDK) Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cyclin-Dependent Kinase (CDK) Inhibitors Production Mode & Process
7.4 Cyclin-Dependent Kinase (CDK) Inhibitors Sales and Marketing
7.4.1 Cyclin-Dependent Kinase (CDK) Inhibitors Sales Channels
7.4.2 Cyclin-Dependent Kinase (CDK) Inhibitors Distributors
7.5 Cyclin-Dependent Kinase (CDK) Inhibitors Customers
8 Cyclin-Dependent Kinase (CDK) Inhibitors Market Dynamics
8.1 Cyclin-Dependent Kinase (CDK) Inhibitors Industry Trends
8.2 Cyclin-Dependent Kinase (CDK) Inhibitors Market Drivers
8.3 Cyclin-Dependent Kinase (CDK) Inhibitors Market Challenges
8.4 Cyclin-Dependent Kinase (CDK) Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer